Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets

Area of Science:

• Immunology
• Endocrinology
• Autoimmunity

Background:

• Type 1 diabetes (T1D) involves an autoimmune attack on beta cells.
• Understanding T1D autoantigens is crucial for developing monitoring assays and therapies.
• Recent progress has been made in the last five years.

Purpose of the Study:

• To review advancements in mechanistic understanding, diagnostic monitoring, and therapeutic modulation of T1D autoantigen-specific immune responses.
• To highlight the potential of new technologies for exploring human cellular immune responses in T1D.
• To discuss challenges and future directions for autoantigen-based immunotherapy in T1D.

Main Methods:

• Review of recent literature (last 5 years) on T1D autoantigens and immune responses.
• Analysis of mechanistic understanding, diagnostic tools, and therapeutic strategies.
• Discussion of novel technologies and preclinical/in vitro findings.

Main Results:

• Technical progress in monitoring tools has been achieved.
• Exploitation of new technologies for multiplexed immune response analysis in T1D is needed.
• Non-conventional antigen presentation may play a role but is under-explored in human T1D.
• Direct therapeutic autoantigen administration has yielded disappointing results.

Conclusions:

• Novel autoantigen administration methods are required for successful T1D immunotherapy.
• Translating mechanistic insights from preclinical studies and in vitro human cell research is essential.
• Combination therapies, including CD3 antibodies, may enhance the efficacy of autoantigen-based treatments for T1D.